Ventracor (ASX: VCR) today announced US Food & Drug Administration (FDA) approval to use the new version of its VentrAssist(tm) left ventricular assist device (LVAD) in its US clinical trial program.
Phosphagenics Limited ("Phosphagenics") (ASX: POH)(AIM: PSG)(OTCQX: PPGNY) today announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin without causing any disruption or irritation.
Ventracor (ASX: VCR) today welcomed a major milestone in the growth of the worldwide industry for Left Ventricular Assist Devices (LVADs).
The Annual General Meeting of Ventracor Limited was held in Brisbane on 24 October and was well attended. We were very grateful and pleased to see the continuing interest and support by our shareholders. All resolutions put to the meeting were passed.
Ventracor (ASX: VCR) today announced 10 US hospitals have implanted at least one VentrAssist(tm) as part of its US clinical trials, and that more centres are trained and awaiting availability of patients.
Signing of an exclusive agreement with one of the world's largest pharmaceutical groups in December 2006 to develop the UnitractTM Prefilled Syringe for one of its major drug products. After a successful review of product specifications in July 2007, both parties are now finalizing an extension of this agreement.
Unilife Medical Solutions Limited ("Unilife") (ASX: UNI) is pleased to announce the successful testing of its fully automated assembly line developed for the manufacture of the Unitract(tm) range of 1mL syringes at its US facility, Integrated BioSciences Inc ("IBS")
